CytRX Corporation (CYTR:NASDAQ) Annual Reports & Investor Relations Material

Overview

CytRx Corporation is a biopharmaceutical company that focuses on research and development in the field of oncology. Their drug development pipeline includes INNO-206, which is currently in Phase Ib clinical trial and completing Phase Ib/II clinical trial for treatment of soft tissue sarcomas. They also have tamibarotene, which is currently in Phase IIb clinical trial for non-small-cell lung cancer and is undergoing clinical trial for acute promyelocytic leukemia.

Annual Reports

Frequently Asked Questions

What is CytRX Corporation's ticker?

CytRX Corporation's ticker is CYTR

What exchange is CytRX Corporation traded on?

The company's shares trade on the NASDAQ stock exchange

Where are CytRX Corporation's headquarters?

They are based in Los Angeles, California

How many employees does CytRX Corporation have?

There are 1-10 employees working at CytRX Corporation

What is CytRX Corporation's website?

It is http://www.cytrx.com/

What type of sector is CytRX Corporation?

CytRX Corporation is in the Healthcare sector

What type of industry is CytRX Corporation?

CytRX Corporation is in the Biotechnology industry

Who are CytRX Corporation's peers and competitors?

The following five companies are CytRX Corporation's industry peers:

- Cortexyme, Inc.

- Valaris

- Revance Therapeutics

- Sirtex Medical Limited

- 4D Pharma PLC